Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company ...

OPERA-02: a phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 LAWRENCEVILLE, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous ...

Detailed price information for Xilio Therapeutics Inc (XLO-Q) from The Globe and Mail including charting and trades.

Third Independent Data Monitoring Committee (IDMC) review confirms safety and continuation of the study 94 patients enrolled out of 102 planned across Korea and the U.S. Interim ...

MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data on Vanoglipel (DA-1241), a ...

The presentation will feature clinical data from the recently announced Phase IIa (ENX-CL-05-001) 3-month topline data readout for Allocetra™ in patients with moderate-to-severe knee osteoarthritis ...

A rising wave of tumor-agnostic therapies were one of ESMO’s themes, highlighted during the opening press conference by Toni ...

The company presented data from two trials: ARV-102-101 ... Dose and Multiple Ascending Dose Trial in Healthy Volunteers (Poster 904): Interim Single Ascending Dose Data from a Phase 1 Trial in ...

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel ...